Paasa Logo
Karyopharm Therapeutics Inc. logo
KPTINASDAQMarket closedOpens 9:30am ET

Karyopharm Therapeutics Inc.

$1.62Last updated
+$0.00 (0.00%)Past day
Timezone

Karyopharm Therapeutics Inc. (NASDAQ: KPTI) is trading at $1.62, about ₹156 at today's USD/INR rate, as of 28 Sep 2026, 4:00 PM ET. Indian residents can buy Karyopharm Therapeutics from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$1.59
Previous close:$1.62
Volume:326.53K

Today's low

$1.54

Today's high

$1.66

52 week low

$1.24

52 week high

$10.99

KPTI opened at $1.59, closed previously at $1.62, and has traded between $1.24 and $10.99 over the past 52 weeks.

About

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Country
US
CEO
Richard A. Paulson
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
228
Sector
Healthcare
IPO date
06/11/2013

Key statistics

Avg. volume

1.25M

Market cap

$36.71M

P/E Ratio

-0.07

Price-to-sales ratio

0.25

Enterprise value

$197.62M

Free cash flow yield

-177.99%

Debt-to-equity ratio

-0.65

Return on equity

77.63%

ROIC

376.87%

Beta

0.95

Dividend yield

0.00%

Last dividend

$0.00

Financial overview

Revenue

$146.07M

Earnings per share

-$17.93

Free cash flow

-$75.37M

Net profit margin

-153.28%

Gross margin

95.88%

EBITDA

-$149.85M

Revenue growth

0.57%

Similar securities

This is not an investment recommendation

How to buy Karyopharm Therapeutics from India

Indian residents can buy Karyopharm Therapeutics shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Karyopharm Therapeutics and place an order

    Find Karyopharm Therapeutics by name or by its ticker, KPTI, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Karyopharm Therapeutics trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Karyopharm Therapeutics position in USD and INR. Karyopharm Therapeutics pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.

Read the full guide: how to invest in Karyopharm Therapeutics from India

Trading and taxes when buying Karyopharm Therapeutics from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
NoneKaryopharm Therapeutics does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Karyopharm Therapeutics stock?

Yes. Karyopharm Therapeutics (KPTI) has been listed on NASDAQ since 2013, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Karyopharm Therapeutics share cost in rupees?

One Karyopharm Therapeutics share is $1.62 — about ₹156 at a USD/INR rate of 96.07 on 28 Sep 2026. Both the Karyopharm Therapeutics price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Karyopharm Therapeutics from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy whole shares of Karyopharm Therapeutics?

Yes. One Karyopharm Therapeutics share is $1.62, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Karyopharm Therapeutics.

How are gains on Karyopharm Therapeutics shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Karyopharm Therapeutics price. Paasa issues a capital-gains statement for your return.

Does Karyopharm Therapeutics pay a dividend?

No. Karyopharm Therapeutics does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.

When can I trade Karyopharm Therapeutics from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Karyopharm Therapeutics shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Karyopharm Therapeutics shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Karyopharm Therapeutics holding, its cost and its closing value.

How do I sell Karyopharm Therapeutics and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.